The nomination committee proposes changes to Scandinavian ChemoTech's board to strengthen the focus on commercialization
The nomination committee in Scandinavian ChemoTech AB ("ChemoTech") has decided to propose changes to the board to provide better conditions for, and create a clearer focus on, commercialization of the company's products.After ChemoTech built a clinical platform and strategy in recent years to take the company's technology into areas such as deep-seated tumors and immunotherapy, the company is now entering a commercialization phase in earnest. Against this background, the nomination committee nominates Robin Sukhia as the new chairman of the company's board. Robin has solid experience in